Lilly Walks Away From Lupus Indication for Blockbuster JAK Inhibitor Olumiant, Anticipates CRL on the Drug’s Atopic Dermatitis Indication

Eli Lilly has given up on its blockbuster rheumatoid arthritis drug Olumiant as a treatment for lupus.
Source: Drug Industry Daily